By John Carroll Novartis ($NVS) CEO Joe Jimenez took a minute during a recent interview with Fortune to explain the company’s drug development strategy. Rather than go after a blockbuster indication, Novartis scientists are more focused on pathways. By pursuing a particular disease pathway with a drug designed to treat a rare disease, Novartis improves …
By John Carroll While Wall Street has been transfixed by signs that Pfizer CEO Ian Read is preparing to sell off large chunks of its business so it can concentrate on pharmaceutical sales and new drug development to replace the blockbusters slated to lose patent protection, Read has been pushing full-steam-ahead on plans to radically …
By John Carroll Sanofi-Aventis CEO Chris Viehbacher (photo) took the podium at an MIT event to lay out the pharma company’s R&D strategy, once again voicing his displeasure with big internal research operations and laying out a new approach to investing in small biotech companies. “My goal as CEO is never to inaugurate a new …
